AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05128552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chest physiotherapy
Description: Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
Study NCT05128552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional chest physiotherapy
Description: Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
Study NCT00499694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
Study NCT00499694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: satraplatin
Description: 80 mg/m(2), Orally, Days 1-5, every 35 days
Study NCT02326194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose Ebola Zaire vaccine (Ad5-EBOV)
Description: one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
Study NCT02326194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose Ebola Zaire vaccine (Ad5-EBOV)
Description: two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
Study NCT02326194 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo (one dose)
Description: placebo, one doses
Study NCT02326194 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo (two doses)
Description: placebo, two doses, with one dose to each arm at a same time.
Study NCT02104375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: 2 weeks of L-citrulline supplementation (6g/day).
Study NCT02104375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-citrulline
Description: 2 weeks of L-citrulline supplementation (6g/day).
Study NCT02669056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-HT measurement
Study NCT02669056 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 5-HT measurement
Study NCT02669056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cerebral MRI
Study NCT02669056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video recording
Study NCT02669056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Study NCT02669056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: growth curves
Study NCT02669056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASQ questionnaire
Study NCT01526850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: mesenchymal stem cell
Description: Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
Study NCT01526850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine and Glucocorticoid
Description: Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
Study NCT03417375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Sinus Augmentation
Description: Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
Study NCT03417375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Sinus Augmentation
Description: Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
Study NCT03180788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traction assisted ESD
Description: A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD
Study NCT03180788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ESD
Description: Endoscopic submucosa dissection
Study NCT02152111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut flour
Description: Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.
Study NCT02152111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Patients were instructed to follow the dietary treatment for 6 months.
Study NCT04527679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC combined Lenvatinib
Description: 1. GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~2. Lenvatinib (\<60kg: 8mg /d; ≥60kg, 12mg).
Study NCT00202228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cofactor supplementation (thiamine, riboflavin, L-carnitine)
Description: Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
Study NCT01999400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apriso 375 mg capsule x 3 with 240 mL water; single dose
Study NCT03426735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry heat
Description: Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
Study NCT03426735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry cold
Description: Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
Study NCT03586427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241751
Description: AGN-241751 administered orally as a single tablet
Study NCT01999400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lialda 1200 mg tablet x 1 with 240 mL water; single dose
Study NCT03586427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally as a single tablet
Study NCT02885831 — intervention group
Intervention type: DEVICE
Intervention: Abduction splintage
Description: Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
Study NCT04025736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml
Description: Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
Study NCT04025736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
Study NCT02160184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)
Study NCT03498963 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bronchoalveolar lavage
Description: Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
Study NCT02136446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchoGlo Nerve Block Catheter
Description: Catheter used for a paravertebral anesthesia block
Study NCT02136446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pajunk® Nerve Block Catheter
Description: Nerve Block Catheter
Study NCT01882101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation
Description: 34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
Study NCT01882101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
Study NCT02477072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
Study NCT03044756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omit Citrotide 0.25 dose on the day of triggering of ovulation
Description: Omit Citrotide 0.25 dose on the day of triggering of ovulation
Study NCT00795392 — intervention group
Intervention type: OTHER
Intervention: ASA scale
Description: ASA scale evaluation before operation
Study NCT01999400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose
Study NCT00795392 — intervention group
Intervention type: OTHER
Intervention: Full-scale psychological assessment
Description: Full-scale psychological evaluation before operation
Study NCT04362059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVSurf Drug Delivery System
Description: Device introduces surfactant to the patients lungs
Study NCT04362059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care treatment for respiratory illness
Study NCT02823886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI at D7
Description: The infarct size measured on MRI at 7 days.
Study NCT02823886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
Study NCT00379210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training (MMT)
Description: 8-week training course in mindfulness meditation
Study NCT00379210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education course
Description: 8-week course in nutrition
Study NCT04301947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard warm-up protocol
Description: Stationary cycling and lower limb stretching exercises
Study NCT04301947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluteal activation warm-up protocol
Description: Standard warm-up protocol + Clam exercise (3 sets of 12 repetitions each)
Study NCT01028976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid)
Description: 1000 mg/day (two 500-mg tablets), 8 weeks
Study NCT01028976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (two 500-mg tablets), 8 weeks
Study NCT00821093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 µg
Description: Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study NCT00821093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 50 µg
Description: Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
Study NCT00821093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study NCT00821093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salmeterol
Description: Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
Study NCT00741923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: navy beans added to regular diet
Description: 5 cups per week of commercially available white beans for 4-weeks
Study NCT01133678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel (175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus 5 mg PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
Study NCT01133678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
Study NCT00135226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT00135226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Ethyl Esters
Study NCT00135226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Aspirin
Study NCT00135226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Omega-3 Ethyl Esters
Study NCT00513149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg loading
Study NCT03606187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimgenics SCS Programming Approach
Description: Stimgenics SCS Programming approach Using Intellis(TM) SCS system
Study NCT03606187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard SCS Programming Approach
Description: Standard SCS Programming approach using Intellis(TM) SCS system
Study NCT00394550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supraglottoplasty with laser
Description: Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children
Study NCT00394550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supraglottoplasty with laser
Description: laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
Study NCT03450954 — intervention group
Intervention type: PROCEDURE
Intervention: Amniotic membrane transplant
Description: Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
Study NCT02265250 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries
Study NCT02265250 — intervention group
Intervention type: OTHER
Intervention: PET/MRI
Description: Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries
Study NCT02265250 — intervention group
Intervention type: OTHER
Intervention: Laboratory blood test
Description: Cardiovascular biomarkers
Study NCT01647893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTB-001
Description: IV bolus or IV infusion
Study NCT04343755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
Study NCT00838240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV
Study NCT00838240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00838240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT01456169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan medoxomil/placebo
Description: Azilsartan medoxomil and placebo to chlorthalidone combination tablets
Study NCT01456169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil - chlorthalidone
Description: Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
Study NCT01011140 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: 10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
Study NCT05356780 — intervention group
Intervention type: DEVICE
Intervention: Aligner
Description: A method of straightening teeth without fixed braces
Study NCT02292446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
Study NCT01687101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STOPAIN topical gel
Description: STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
Study NCT04656457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Treadmill is not used to harness power, but as exercise machines for running or walking in one place. Rather than the user powering the mill, the machine provides a moving platform with a wide conveyor belt driven by an electric motor or a flywheel. The belt moves to the rear, requiring the user to walk or run at a speed matching that of the belt. The rate at which the belt moves is the rate of walking or running. Thus, the speed of running may be controlled and measured
Study NCT04656457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resisted exercises
Description: Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting)
Study NCT01112787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Foam
Description: Tazarotene Foam
Study NCT01112787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam
Study NCT01112787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Laural Sulfate
Description: Sodium Laural Sulfate
Study NCT01112787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Distilled Water
Study NCT05899400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diascopic iON Image Analysis System
Description: A scanning digital optical train that images sputum slides for automated analysis by a tuberculosis detecting algorithm
Study NCT00392730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Remove Mn from PN if evidence of increased brain Mn on MRI
Description: Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
Study NCT02553395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phenacite (Test) contact lens
Study NCT02553395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A contact lens
Study NCT04270799 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Classification
Description: Patient's scans will be used as input into in-house software to extract multiple radiomics features. These features will be used to develop a risk-signature which can predict malignancy risk. Patient scans will also be used as input into deep learning/convolutional neural network models to perform automated imaging classification.
Study NCT03619772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral
Description: Participants will control game using EMG from both upper limbs.
Study NCT03619772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral
Description: Participants will control game using EMG from the more impaired upper limb.
Study NCT04086095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neofact application aid
Description: The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).